Fresh Tracks Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Fresh Tracks Therapeutics has a total shareholder equity of $9.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $11.6M and $1.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$10.87m |
Equity | US$9.93m |
Total liabilities | US$1.66m |
Total assets | US$11.59m |
Recent financial health updates
Recent updates
Brickell Biotech changes name to Fresh Tracks Therapeutics
Sep 07Brickell Biotech GAAP EPS of -$0.01 beats by $1.43, revenue of $4.32M beats by $1.18M
Aug 11Brickell Biotech regains Nasdaq compliance for minimum bid price requirement
Jul 20Here's Why Brickell Biotech (NASDAQ:BBI) Must Use Its Cash Wisely
Feb 14Brickell Biotech Advances To Phase III As It Eyes Commercialization
May 10Brickell Biotech completes patient enrollment in late-stage sweat disorder study
Apr 27Brickell Biotech's(NASDAQ:BBI) Share Price Is Down 16% Over The Past Year.
Jan 06Brickell Biotech (BBI) Investor Presentation - Slideshow
Dec 02Brickell Bio to launch sofpironium bromide gel, 5% in Japan on November 26
Nov 18Financial Position Analysis
Short Term Liabilities: FRTX's short term assets ($11.6M) exceed its short term liabilities ($1.7M).
Long Term Liabilities: FRTX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: FRTX is debt free.
Reducing Debt: FRTX currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FRTX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: FRTX has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 0.3% each year.